Article Text
Abstract
This 14th best practice review is the second of a pair that examines tumour marker requesting primary care situations. This review considers carbohydrate antigen 125, α-fetoprotein and human chorionic gonadotropin. It is presented in question–answer format, referenced for each question. The recommendations represent a précis of guidance found using a standardised literature search of national and international guidance notes, consensus statements, health policy documents and evidence-based medicine reviews, supplemented by MEDLINE EMBASE searches to identify relevant primary research documents. They will be updated periodically to take into account new information.
- Cholesterol
- lipids
- lipoproteins
- laboratory management
- laboratory computing
- medical education
- management
- evidence-based pathology
- colorectal cancer
- gall bladder
- oncogenes
- P53
- pancreas
- nutrition
- molecular biology
- laboratory tests
- chemical pathology
- diagnosis
- tumour markers
- urogenital pathology
- liver cancer
Statistics from Altmetric.com
Footnotes
Funding This work has been supported (in alphabetical order) by the Association of Clinical Biochemists*, Association of Clinical Pathologists*, Association of Medical Microbiologists, British Society for Haematology, Royal College of General Practitioners, Royal College of Pathologists* and the Sowerby Centre for Health Informatics in Newcastle (SCHIN), whose representatives have contributed to the reviewing process. The opinions stated are, however, those of the authors. *These organisations contributed direct funding to support the project start up.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.